The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-l1 antibodies in tumor immunotherapy in China: A bibliometrics study

• Published in: Medicine (Baltimore) Vol. 97; no. 15; p. e0276
• Main Authors: Zhao, Xiaoqin, He, Liangmei, Mao, Kaiyun, Chen, Daming, Jiang, Hongbo, Liu, Zhiping
• Format: Journal Article
• Language: English
• Published: United States The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved 01.04.2018; Wolters Kluwer Health
• Subjects: B7-H1 Antigen - immunology; Bibliometrics; Biomedical Research; China; CTLA-4 Antigen - immunology; Databases, Factual; Humans; Immunosuppressive Agents - pharmacology; Immunotherapy - methods; Immunotherapy - statistics & numerical data; Neoplasms - therapy; Programmed Cell Death 1 Receptor - immunology; Systematic Review and Meta-Analysis

Using bibliometrics, we analyzed the research status of immune checkpoint blockade (ICB, a popular tumor immunotherapy method represented by antibodies targeted CTLA-4 and PD-1/PD-L1) in tumor immunotherapy in China during the past 2 decades. Articles in Science Citation Index Expanded (SCI-EXPANDED...